GlassScriptPhysician profile
Sarah B Holcomb
NPI 1043546930
$3,527.80
in general payments reported to CMS, 2019-2025
30 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $112 · 2022: $41.37 · 2023: $1,009 · 2024: $1,985 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,354.15 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.10 | 2023-2025 | |
| Pfizer INC. | $379.40 | 2023-2025 | |
| Glaxosmithkline, LLC. | $371.97 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $291.45 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $285.54 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $179.50 | 2023-2024 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $176.71 | 2023-2024 | Veozah |
| Novo Nordisk INC | $119.07 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $112.06 | 2020 | |
| Janssen Pharmaceuticals, INC | $97.95 | 2023-2024 | Spravato |
| Axsome Therapeutics, INC. | $95.24 | 2024 | Auvelity |
| Dexcom, INC. | $65.72 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $62.79 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.39 | 2023-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.55 | 2024-2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $37.53 | 2023-2024 | Rexulti |
| Esperion Therapeutics, INC. | $31.51 | 2023 | Nexletol |
| Nevro Corp. | $28.20 | 2022-2024 | Senza |
| Organon LLC | $27.64 | 2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.05 | 2023 | Xifaxan, Trulance |
| Kyowa Kirin, INC. | $25.69 | 2023 | Crysvita |
| Supernus Pharmaceuticals, INC. | $23.32 | 2023 | Qelbree, Xyosted, Tlando |
| Shield Therapeutics INC | $21.43 | 2024 | |
| Halozyme INC | $19.65 | 2023 | |
| Abbott Laboratories | $19.35 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $17.84 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $17.41 | 2024 | Vaqta, Capvaxive, Gardasil |
| Mayne Pharma Commercial LLC | $14.61 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.16 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $12.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Holcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.